Versikine for inducing and potentiating an immune response
Disclosed are methods, kits, polypeptides, and pharmaceutical compositions for inducing an immune response in a subject, which may include a T-cell mediated immune response. The methods comprise administering to the subject, or to explanted cells of the subject, a pharmaceutical composition comprising an effective amount of versikine or a variant of versikine that induces the T-cell mediated immune response. The methods, kits, polypeptides, and pharmaceutical compositions may be used, in particular, to treat a subject having a cell proliferative disease or disorder.
1. A method for inducing and/or potentiating a T-cell mediated immune response in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of a molecule comprising a versican fragment or variant thereof, wherein the versican fragment or variant thereof consists of the amino acid sequence of SEQ ID NO: 5, SEQ ID NO:6, or SEQ ID NO: 7; and wherein the molecule induces and/or potentiates the T-cell mediated immune response.
2. The method of claim 1 , wherein the molecule does not have any chondroitin sulfate side chains.
3. The method of claim 1 , wherein administering comprises injecting locally into tumor tissue of the subject the pharmaceutical composition comprising an effective amount of the molecule.
4. A method for inducing and/or potentiating a T-cell mediated immune response in a subject in need thereof, wherein the subject has a cell proliferative disease or disorder, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of a molecule comprising a versican fragment or variant thereof, wherein the versican fragment or variant thereof consists of the amino acid sequence of SEQ ID NO: 5, SEQ ID NO:6, or SEQ ID NO: 7; and wherein the molecule induces and/or potentiates the T-cell mediated immune response.
5. The method of claim 4 , wherein the molecule does not have any chondroitin sulfate side chains.
6. The method of claim 4 , wherein administering comprises injecting locally into tumor tissue of the subject the pharmaceutical composition comprising an effective amount of the molecule.